Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma: Clinical Genitourinary Cancer

S Nazzani, F Preisser, E Mazzone, M Marchioni, M Bandini, Z Tian, FA Mistretta, SF Shariat, D Soulières, E Montanari, P Acquati, A Briganti, L Carmignani, PI Karakiewicz

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Few data examined the potential survival benefit of chemotherapy (CHT) in the setting of metastatic upper urinary tract urothelial carcinoma (mUTUC). We hypothesized that a survival benefit might be associated with the use of CHT in nonsurgically treated primary mUTUC and tested this hypothesis within a large population-based cohort. Patients and Methods: Within the Surveillance, Epidemiology, and End Results database (2004-2014), we identified 539 patients with nonsurgically treated primary mUTUC. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier plots, as well as multivariable Cox regression models relying on IPTW and landmark analyses, were used to test the effect of CHT versus no CHT on overall mortality and cancer-specific mortality. Results: Of 539 patients with metastatic UTUC, 277 (51.4%) underwent CHT. In nonadjusted and IPTW-adjusted Kaplan-Meier plots, CHT was associated with better overall survival (9 vs. 2 months; P
Original languageEnglish
Pages (from-to)97-e103
JournalClinical Genitourinary Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma: Clinical Genitourinary Cancer'. Together they form a unique fingerprint.

Cite this